News & Analysis as of

Mergers › Spinoffs › Initial Public Offering (IPO)

Paul Hastings LLP

Biotech Spin-Off Transactions

Paul Hastings LLP on

As we previously discussed (here and here), the biotech mergers and acquisitions market currently faces significant headwinds. These challenges include frozen capital markets, regulatory uncertainty at the Food and Drug...more

Skadden, Arps, Slate, Meagher & Flom LLP

Capital Markets Alert: SEC Approves NYSE Rules to Facilitate Direct Listings

Skadden, Arps, Slate, Meagher & Flom LLP on

On February 2, 2018, the SEC approved the New York Stock Exchange’s proposal to permit qualifying private companies to use “direct listings” to list their shares on the NYSE and become publicly traded without conducting an...more

Morris James LLP

Fraud Vitiated Special-Committee Process in Dole Merger

Morris James LLP on

In a self-interested transaction between a company and its controlling stockholder, the operative standard of judicial review under Delaware law is the most rigorous: entire fairness standard of review. To obtain the least...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide